Skip to main content

Table 2 Baseline characteristics in each study group

From: Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease

 

Patients with cryoglobulinemia

(N = 56)

Patients with SLE (N = 5)

Patients with CKD (hypertensive or diabetic) (N = 111)

Patients undergoing hemodialysis (N = 48)

Patients after kidney transplant (N = 12)

Gender

M: 20 pts. (35.8%)

F: 36 pts. (64.2%)

M: 0 pts.

F: 5 pts. (100%)

M: 51 pts. (46%)

F: 60 pts. (54%)

M: 27 pts. (56.2%)

F: 21 pts. (43.8%)

M: 7 pts. (58.3%)

F: 5 (41.6%)

Fibrosis

F2: 48 pts. (85.7%)

F3: 5 pts. (8.9%)

F4: 3 pts. (5.3%)

F2: 4 pts. (80%)

F3: 1 pts. (20%)

F4: 0 pts

F2: 54 pts. (48.6%)

F3: 49 pts. (44.1%)

F4: 8 pts. (7.2%)

F2: 28 pts. (58.3%)

F3: 12 pts. (25%)

F4: 8 pts. (16.6%)

F2: 5pts (41.6%)

F3: 7 pts. (58.3%)

F4: 0 pts

Stage of CKD

Stage 2: 13 pts. (23.2%)

Stage 3: 39 pts. (69.6%)

Stage 4: 4 pts. (7.1%)

Class 2 nephritis: 3 pts. (60%)

Class 3 nephritis: 1 pts. (20%)

Class 4 nephritis: 1 pts. (20%)

Stage 2: 62 pts. (55.8%)

Stage 3: 31 pts. (27.9%)

Stage 4: 18 pts. (16.2%)

 

Stage 2: 0 pts.

Stage 3: 12 pts. (100%)

Stage 4: 0 pts

Hemglobin

Normal: 7 pts. (12.5%)

Mild anemia: 49 pts. (87.5%)

Normal: 2 pts. (40%)

Mild anemia: 3 pts. (60%)

Normal: 103 pts. (92.8%)

Mild anemia: 8 pts. (7.2%)

Normal: 0 pts.

Mild anemia: 29 pts. (60.5%)

Moderate anemia: 19 pts. (39.5%)

Normal: 8 pts. (66.6%)

Mild anemia: 4 pts. (33.3%)